GYRE Gyre Therapeutics
- 11.360
- +0.950+9.13%
- 11.930
- +0.570+5.02%
Gyre Therapeutics News
Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy
Gyre Therapeutics (GYRE) said late Thursday that the Chinese National Medical Products Administration approved its subsidiary Gyre Pharmaceuticals' investigational new drug application for F230, its t
Gyre Therapeutics Inc: Clinically Approved by China's National Drug Administration to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics Inc: Clinically Approved by China's National Drug Administration to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Express News | Gyre Therapeutics Inc: Receives Ind Approval From China's Nmpa to Evaluate F230 for Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics files for $150 million hybrid shelf offering — SEC filing
Gyre Therapeutics files for $150 million hybrid shelf offering — SEC filing
Express News | Gyre Therapeutics Files for Mixed Shelf Offering for $150 Mln - SEC Filing
Express News | Gyre Therapeutics Inc Files for Shelf of up to 1.1 Mln Shares of Common Stock by Selling Stockholder - SEC Filing
Gyre Pharmaceuticals Receives IND Approval From China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results.Bank of Montreal posted quarterly adjusted
Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 300 points on Wednesday.Shares of HEICO Corporation (NYSE:HEI) rose sharply during Wednesday's session following a second-quarter ear
Gyre Therapeutics Announces Expected Addition to the Russell 2000 and Russell 3000 Indexes
SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ
Gyre Therapeutics | 10-Q: Quarterly report
Gyre Therapeutics Reports First Quarter 2024 Earnings
Gyre Therapeutics (GYRE.US): The 2024 Q1 financial report achieved revenue of US$27.172 million, with a previous value of US$24.931 million; earnings per share of US$0.03, compared with a previous value of US$0.03.
Gyre Therapeutics (GYRE.US): The 2024 Q1 financial report achieved revenue of US$27.172 million, with a previous value of US$24.931 million; earnings per share of US$0.03, compared with a previous value of US$0.03.
Gyre Therapeutics Q1 EPS $0.03, Same YoY, Sales $27.17M Up From $24.93M YoY
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share. This is unchanged from the same period last year. The company reported $27.17 million in sales this quarter. This is a
Gyre Therapeutics(GYRE.US) Director Sells US$282.58K in Common Stock
$Gyre Therapeutics(GYRE.US)$ Director USMAN NASSIM sold 20,000 shares of common stock on May 1, 2024 at an average price of $14.13 for a total value of $282.58K.Source: Announcement What is statement
Form 144 | Gyre Therapeutics(GYRE.US) Director Proposes to Sell 282.47K in Common Stocks
SEC FILLINGS DISCLOSED/ May 1, $Gyre Therapeutics(GYRE.US)$ Director NASSIM USMAN intends to sell 20,000 shares of its common stock on May 1, with a total market value of approximately $282.47K. NAS
Public Companies Are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) Biggest Owners and Were Rewarded After Market Cap Rose by US$137m Last Week
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) rose sharply during Thursday's session. Enliven Therapeutics an
Gyre Therapeutics(GYRE.US) Director Sells US$323K in Common Stock
$Gyre Therapeutics(GYRE.US)$ Director USMAN NASSIM sold 20,000 shares of Common Stock on Apr 1, 2024 at an average price of $16.15 for a total value of $323K.Source: Announcement What is statement of
Analysis
Price Target
No Data
